Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

FTC affirms cancer cures case ruling

This article was originally published in The Tan Sheet

  • News

Executive Summary

Daniel Chapter One must notify customers it made deceptive and unsubstantiated cancer cure claims for its herbal products after failing in its appeal of an administrative law judge's ruling to uphold Federal Trade Commission charges. The commission's unanimous 1opinion, announced Dec. 24, says respondents Daniel Chapter One and James Feijo "lacked a reasonable basis to substantiate" claims their products BioShark, 7 Herb Formula and others inhibit tumor growth and are effective cancer treatments. Like other companies charged in FTC's 2008 enforcement sweep against bogus cancer cure claims, Providence, R.I.-based Daniel Chapter One is enjoined from making such claims without supporting scientific evidence (2"The Tan Sheet" Aug. 17, 2009, In Brief)

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS103660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By